#United States #New Orleans #Breast Cancer #Optical Coherence #Perimeter Imaging

Perimeter Medical Imaging AI Showcases Innovation at Fall Summit

Perimeter Medical Imaging AI Inc. has recently made headlines by exhibiting its groundbreaking imaging technology at the Aptitude Health/TME's Fall Summit, titled "Take the Lead in Breast Cancer Care," which took place in New Orleans on September 26-27, 2025. This influential gathering brought together approximately 50 of the nation’s leading breast cancer physicians, healthcare professionals, and industry experts to engage in high-level discussions about advancing care for high-risk and newly diagnosed breast cancer patients.

Perimeter CEO, Adrian Mendes, emphasized the potential of their Optical Coherence Tomography (OCT) technology in the operating room. He stated that the ability to visualize margins during surgery, enhanced by artificial intelligence, represents a significant leap forward in intraoperative patient care. "This intimate forum provides us with a unique opportunity to present our device to a prestigious group of physicians dedicated to revolutionizing cancer care," Mendes expressed.

The Perimeter S-Series OCT, a crucial tool for real-time imaging, received FDA clearance in 2021, aimed primarily at general imaging tasks. Furthermore, an AI-assisted version of this technology is currently under FDA evaluation for intraoperative breast cancer imaging, which could further improve surgical precision. The summit itself is structured to encourage collaborations among surgeons, oncologists, pathologists, genetic specialists, and industry leaders through closed-door roundtable discussions and breakout sessions. These collaborative efforts focus on innovative diagnostic practices and therapeutic insights, aimed at improving real-world clinical outcomes and tackling challenges faced in the field.

About Perimeter Medical Imaging AI, Inc.

Perimeter Medical Imaging AI operates out of Toronto, Canada, and Dallas, Texas, to reshape the landscape of cancer surgery. Their innovative imaging tools are designed to provide ultra-high-resolution, real-time visualization of excised tissues at the cellular level. Available throughout the United States, the FDA-cleared Perimeter S-Series OCT system allows for crucial real-time imaging. Moreover, the investigational Perimeter B-Series OCT equipped with ImgAssist AI is currently undergoing a pivotal clinical trial, buoyed by a US$7.4 million grant from the Cancer Prevention and Research Institute of Texas.

The company’s ticker symbol, "PINK," is a nod to the pink ribbons associated with Breast Cancer Awareness Month, further highlighting its commitment to breast cancer care.

However, it is important to note that the Perimeter B-Series OCT is restricted for investigational use under U.S. law and is not available for sale in the United States. The Perimeter S-Series OCT holds a 510(k) clearance for general imaging purposes but has not been evaluated specifically for breast tissue or breast cancer applications. Consequently, claims regarding its safety and effectiveness for these uses remain unvalidated.

Conclusion

The Fall Summit represented a critical platform for Perimeter and other stakeholders to bridge the gap between technology and patient care in breast cancer surgery. The advancement of imaging technologies, coupled with the collaborative nature of experts at such events, signifies a brighter future for breast cancer treatment. As Perimeter continues to innovate, the focus remains on providing effective solutions that directly address unmet medical needs and improve outcomes for patients facing breast cancer challenges.